CORRECTION: RVL Pharmaceuticals Q2 Adj. EPS $(0.10) Beats $(0.13) Estimate, Sales $8.26M Miss $10.38M Estimate
Portfolio Pulse from Benzinga Newsdesk
RVL Pharmaceuticals (NASDAQ:RVLP) reported Q2 adjusted EPS of $(0.10), beating the estimate of $(0.13) by 23.08%. However, the company's sales of $8.26M missed the estimate of $10.38M by 20.44%. This represents a 28.57% increase in losses and a 2.25% decrease in sales compared to the same period last year.
August 14, 2023 | 11:12 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
RVL Pharmaceuticals reported better than expected Q2 EPS but missed on sales. This mixed report could lead to uncertainty in the market.
RVL Pharmaceuticals reported a better than expected EPS, which is a positive signal for investors. However, the company missed on sales, which could be a concern. The mixed report could lead to uncertainty in the market, potentially impacting the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100